AmorChem
Venture capital · Montréal, QC, Canada · North America
AmorChem is an early stage venture fund that creates biotech companies from academic research. It finances translational research programs in academia and spins out new biotech companies around therapeutic innovations.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticsacademic researchtranslational researchlife sciencesspinouts
Your fit with AmorChem
Three questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAmorChem lists 11 companies on its own site, 2 of them checked. Its largest theme is Healthcare & Biotech (100%). It shares the most portfolio companies with AQC Capital, Genesys Capital and NEA.
No funding round on record names AmorChem yet, so the figures come from its portfolio page.
Shares portfolio companies with
firms that back the same companies, not always in the same roundShow as a table
| Share | |
|---|---|
| AQC Capital | 1 |
| Genesys Capital | 1 |
| NEA | 1 |
| T1D Fund | 1 |
| Western Technology Investment | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its 1 company with a theme; a company can have twoThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 17% |
Shared portfolio network
firms that back the same companies, and what they share with each otherCompare AmorChem head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Team
4 people, as AmorChem's own site lists them- Inès HolzbaurFounder & Managing Partner
- Kevin McBrideGeneral Partner & CSO
- Patricia LaplantePrincipal
- Liliana TurturicaController
Names and roles from this page of its site; VCinfo keeps nothing else about them. Listed here and want to be removed? Write to us.
Portfolio
2 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| The company's webpage does not provide information on what Inversago does. | Other | Portfolio page | ||
| Liminal BioSciences develops novel small molecule therapeutics for metabolic, fibrotic and inflammatory diseases | Healthcare & Biotech | Portfolio page |
About this data
site last read 20 Nov 2026- Site
- amorchem.com
- Last read
- 20 Nov 2026
- Watching since
- 6 Nov 2026
- Companies checked
- 2
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get AmorChem's profile as data
Pull AmorChem's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/amorchem.com
# also
GET /v1/firms/amorchem.com/portfolio
GET /v1/firms/amorchem.com/coinvestors
GET /v1/firms/amorchem.com/news